Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$831.00 USD

831.00
342,620

+14.35 (1.76%)

Updated Nov 7, 2024 12:23 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB

by Zacks Equity Research

Regulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.

Sanofi's (SNY) Dupixent Prurigo Nodularis NDA Gets Priority Tag

by Zacks Equity Research

The FDA grants priority review to Sanofi's (SNY) sBLA for Dupixent to include adults with prurigo nodularis, a chronic inflammatory skin disease.

SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal

by Zacks Equity Research

SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.

Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates

by Zacks Equity Research

Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)

by Zacks Equity Research

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

Regeneron's (REGN) Evkeeza Positive in Late-Stage Study

by Zacks Equity Research

Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication

by Zacks Equity Research

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

The Zacks Analyst Blog Highlights Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical

by Zacks Equity Research

Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical are part of Zacks top Analyst Blog

Ekta Bagri headshot

Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory News

by Ekta Bagri

Earnings and regulatory updates from Regeneron (REGN) and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.

Kodiak Sciences (KOD) Q1 Loss Widens, Eye Candidate in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports wider-than-expected loss in the first quarter of 2022. Focus is on lead candidate, KSI-301, being developed for treating various retinal vascular diseases.

Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1

by Zacks Equity Research

Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

Ultragenyx's (RARE) Q1 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.

Regeneron (REGN) Q1 Earnings Beat, COVID Antibody Sales Affected

by Zacks Equity Research

Regeneron (REGN) beats on Q1 earnings and sales record year-over-year growth on the solid performance of Dupixent and Eylea.

Regeneron (REGN) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Regeneron (REGN) delivered earnings and revenue surprises of 22.63% and 9.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Will Eylea, Dupixent Buoy Regeneron's (REGN) Q1 Earnings?

by Zacks Equity Research

Regeneron's (REGN) first-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent.

The Zacks Analyst Blog Highlights Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen

by Zacks Equity Research

Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen have been included in this Analyst Blog.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue View

by Zacks Equity Research

Alnylam's (ALNY) earnings and sales fall shy of estimates in the first quarter of 2022. The company cuts 2022 guidance for net product revenues. Shares down.

Indrajit Bandyopadhyay headshot

5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates

by Indrajit Bandyopadhyay

Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.

Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales Rise

by Zacks Equity Research

Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines. Consumer healthcare sales remain strong.

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

Regeneron (REGN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.